Concord Biotech Limited (CONCORDBIO) - Net Assets
Based on the latest financial reports, Concord Biotech Limited (CONCORDBIO) has net assets worth Rs18.27 Billion INR (≈ $197.56 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs20.23 Billion ≈ $218.80 Million USD) and total liabilities (Rs1.96 Billion ≈ $21.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Concord Biotech Limited tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs18.27 Billion |
| % of Total Assets | 90.29% |
| Annual Growth Rate | 18.67% |
| 5-Year Change | 81.39% |
| 10-Year Change | N/A |
| Growth Volatility | 6.23 |
Concord Biotech Limited - Net Assets Trend (2020–2025)
This chart illustrates how Concord Biotech Limited's net assets have evolved over time, based on quarterly financial data. See Concord Biotech Limited defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Concord Biotech Limited (2020–2025)
The table below shows the annual net assets of Concord Biotech Limited from 2020 to 2025. For live valuation and market cap data, see CONCORDBIO market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs18.13 Billion ≈ $196.04 Million |
+18.74% |
| 2024-03-31 | Rs15.27 Billion ≈ $165.10 Million |
+18.34% |
| 2023-03-31 | Rs12.90 Billion ≈ $139.51 Million |
+16.93% |
| 2022-03-31 | Rs11.03 Billion ≈ $119.31 Million |
+10.39% |
| 2021-03-31 | Rs9.99 Billion ≈ $108.08 Million |
+29.75% |
| 2020-03-31 | Rs7.70 Billion ≈ $83.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Concord Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 165.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs17.20 Billion | 94.90% |
| Common Stock | Rs104.62 Million | 0.58% |
| Other Components | Rs819.71 Million | 4.52% |
| Total Equity | Rs18.13 Billion | 100.00% |
Concord Biotech Limited Competitors by Market Cap
The table below lists competitors of Concord Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fila Holdings Corp
KO:081660
|
$1.52 Billion |
|
Jiangsu Dagang Co Ltd
SHE:002077
|
$1.53 Billion |
|
Arcelik AS
IS:ARCLK
|
$1.53 Billion |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
$1.53 Billion |
|
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
|
$1.52 Billion |
|
NRW Holdings Limited
F:3NR
|
$1.52 Billion |
|
Savaria Corporation
TO:SIS
|
$1.52 Billion |
|
Jilin Chemical Fibre Co Ltd
SHE:000420
|
$1.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Concord Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,266,455,000 to 18,127,175,000, a change of 2,860,720,000 (18.7%).
- Net income of 3,716,423,000 contributed positively to equity growth.
- Dividend payments of 915,392,000 reduced retained earnings.
- Other comprehensive income decreased equity by 292,179,000.
- Other factors increased equity by 351,868,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.72 Billion | +20.5% |
| Dividends Paid | Rs915.39 Million | -5.05% |
| Other Comprehensive Income | Rs-292.18 Million | -1.61% |
| Other Changes | Rs351.87 Million | +1.94% |
| Total Change | Rs- | 18.74% |
Book Value vs Market Value Analysis
This analysis compares Concord Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 21.74x to 7.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | Rs62.00 | Rs1347.50 | x |
| 2021-03-31 | Rs95.53 | Rs1347.50 | x |
| 2022-03-31 | Rs105.45 | Rs1347.50 | x |
| 2023-03-31 | Rs123.31 | Rs1347.50 | x |
| 2024-03-31 | Rs145.93 | Rs1347.50 | x |
| 2025-03-31 | Rs173.27 | Rs1347.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Concord Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.50%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.97%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.12x
- Recent ROE (20.50%) is below the historical average (20.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 26.07% | 33.01% | 0.54x | 1.45x | Rs1.04 Billion |
| 2021 | 23.50% | 38.07% | 0.52x | 1.18x | Rs1.35 Billion |
| 2022 | 15.86% | 24.54% | 0.54x | 1.19x | Rs646.08 Million |
| 2023 | 18.61% | 28.14% | 0.56x | 1.17x | Rs1.11 Billion |
| 2024 | 20.18% | 30.30% | 0.60x | 1.11x | Rs1.55 Billion |
| 2025 | 20.50% | 30.97% | 0.59x | 1.12x | Rs1.90 Billion |
Industry Comparison
This section compares Concord Biotech Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,957,131,429
- Average return on equity (ROE) among peers: 8.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Concord Biotech Limited (CONCORDBIO) | Rs18.27 Billion | 26.07% | 0.11x | $1.52 Billion |
| Blue Jet Healthcare Limited (BLUEJET) | $3.40 Billion | 40.73% | 0.58x | $958.43 Million |
| Dishman Carbogen Amcis Limited (DCAL) | $12.02 Billion | 9.09% | 1.15x | $288.43 Million |
| Lyka Labs Limited (LYKALABS) | $682.65 Million | -3.65% | 1.30x | $27.04 Million |
| SMS Lifesciences India Limited (SMSLIFE) | $1.06 Billion | 16.78% | 1.54x | $42.13 Million |
| Supriya Lifescience Limited (SUPRIYA) | $8.15 Billion | 14.61% | 0.13x | $811.42 Million |
| Take Solutions Limited (TAKE) | $109.18 Million | 4.10% | 0.30x | $47.06 Million |
| Zota Health Care LImited (ZOTA) | $2.27 Billion | -24.83% | 0.93x | $418.05 Million |
About Concord Biotech Limited
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenola… Read more